Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results

What Was Tested

The paper reports a study of Octreotide and Somatostatin, published as a randomized controlled trial.

Results are presented from 2 to 3 trials investigating oral octreotide capsules (OOC) as an alternative to injectable somatostatin receptor ligands (iSRLs) in the treatment of acromegaly.

Who Took Part

CH-ACM-01 was an open-label trial (N = 155) and CHIASMA OPTIMAL was a double-blind placebo-controlled (DPC) trial (N = 56), both investigating OOC as maintenance therapy for patients with acromegaly who were biochemical responders receiving iSRLs.

How the Study Was Run

The design is described as randomized, double-blind, open-label and placebo-controlled.

Because people in this Octreotide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Octreotide, so expectations could not easily colour the readings.

Everyone knew when Octreotide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

A placebo (an inactive look-alike) gave the Octreotide group a baseline to be compared against.

What Was Measured

Topics PubMed links to this paper include Acromegaly, Capsules, Human Growth Hormone, Insulin-Like Growth Factor I, Octreotide and Somatostatin.

Author keywords: IGF-I, Oral octreotide, Somatostatin analogs and Somatostatin receptor ligands.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Octreotide and Somatostatin.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Pituitary), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.